February 23, 2021
1 min read
Disclosures: The authors report no relevant financial disclosures.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
ADDED TO EMAIL ALERTS
We were unable to process your request. Please try again later. If you continue to have this issue please contact email@example.com.
Back to Healio
Patients who received Eliquis were at lower risk for post-polypectomy bleeding and thromboembolism than those who received warfarin and other direct oral anticoagulants, according to study results.
Francis KL Chan, from the department of medicine and therapeutics at The Chinese University of Hong Kong, and colleagues wrote that the difference among competing anticoagulants in terms of post-polypectomy bleeding risk has not been fully explored.
“In this territory-wide population-based study, we aimed to evaluate the bleeding and thromboembolic risks after colonoscopic polypectomy among warfarin and [direct oral anticoagulants (DOAC)] users to address the current knowledge gap and unmet clinical need,” they wrote…